The first authorisation for innovative treatment using CAR T-cells for certain types of cancer may soon be granted. The new Board of Director of the Italian Medicines Agency (AIFA) is expected to meet in the coming days and approval for the therapy will be one of the first items on the agenda.
The agreement will involved AIFA and CAR T-cell producer Novartis, with the Italian public healthcare service covering the costs on the basis of the effectiveness of the therapy. The accord would see the healthcare service reimbursing the costs of the therapy if it were to prove effective on the individual patients. Otherwise the company will have to pick up the costs.
SOURCE: http://www.ansa.it
Dennis Palumbo is a thriller writer and psychotherapist in private practice. He's the auth...
Arnaldo Trabucco, MD, FACS is a leading urologist who received his medical training at ins...
You can tell she fills with excitement when she has the chance to show an important archae...
AGENDA 12.00 – 12.15 Light lunch12.15 – 12.30Welcome addresses Lorenzo Mannelli, MD, PhD...
by Claudia Astarita The food farming sector is still one of the engines of Italia...
A volcano near Rome thought to be extinct appears to be waking up and entering a new erupt...
The “Lovers of Modena”, a pair of skeletons so called because they were buried hand-in-han...
One of the most-well known relics in archeological history is leading researchers to belie...